Zacks: Brokerages Expect Solid Biosciences Inc (NASDAQ:SLDB) to Announce -$0.62 EPS
Equities analysts expect that Solid Biosciences Inc (NASDAQ:SLDB) will post earnings of ($0.62) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.66) to ($0.58). Solid Biosciences reported earnings of ($0.55) per share in the same quarter last year, which would suggest a negative year over year growth rate of 12.7%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Solid Biosciences will report full year earnings of ($2.85) per share for the current year, with EPS estimates ranging from ($3.05) to ($2.68). For the next fiscal year, analysts forecast that the company will report earnings of ($2.06) per share, with EPS estimates ranging from ($2.17) to ($1.91). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that follow Solid Biosciences.
Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.76) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.05.
In related news, Director Life Sciences Maste Perceptive bought 2,822,581 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was acquired at an average price of $4.65 per share, with a total value of $13,125,001.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 31.20% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Quantamental Technologies LLC purchased a new stake in Solid Biosciences in the 2nd quarter worth approximately $42,000. Cubist Systematic Strategies LLC purchased a new position in Solid Biosciences during the 2nd quarter worth $70,000. Capital Fund Management S.A. acquired a new stake in Solid Biosciences during the 2nd quarter worth about $107,000. Parametric Portfolio Associates LLC acquired a new position in shares of Solid Biosciences during the 2nd quarter worth approximately $109,000. Finally, Trexquant Investment LP raised its position in shares of Solid Biosciences by 70.4% during the 2nd quarter. Trexquant Investment LP now owns 24,074 shares of the company’s stock worth $138,000 after acquiring an additional 9,947 shares in the last quarter. 46.29% of the stock is owned by institutional investors.
SLDB stock traded up $0.08 during trading on Friday, reaching $10.60. 570,148 shares of the company traded hands, compared to its average volume of 695,131. The business has a 50 day simple moving average of $7.38 and a 200 day simple moving average of $7.60. Solid Biosciences has a 12 month low of $4.32 and a 12 month high of $54.54. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.73 and a current ratio of 5.73. The company has a market capitalization of $454.01 million, a price-to-earnings ratio of -4.71 and a beta of 1.82.
Solid Biosciences Company Profile
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles.
Featured Article: CBOE Russell 2000® Volatility Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.